We are live on ! Find out more
CWG

C WorldWide Group Portfolio holdings

AUM $4.66B
1-Year Est. Return 11.67%
This Fund
S&P 500
This Quarter Est. Return
+6.1%
1 Year Est. Return
+11.67%
3 Year Est. Return
+62.16%
5 Year Est. Return
+69.96%
10 Year Est. Return
+372.2%
AUM
$8.04B
AUM Growth
+$164M
Cap. Flow
-$244M
Cap. Flow %
-3.03%
Top 10 Hldgs %
72.74%
Holding
123
New
10
Increased
29
Reduced
37
Closed
40

Top Buys

Rank Stock Value
1
MSCI icon
MSCI
MSCI
+$171M
2
ELV icon
Elevance Health
ELV
+$30.9M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$16.2M
4
ISRG icon
Intuitive Surgical
ISRG
+$14.8M
5
HUM icon
Humana
HUM
+$13.9M

Top Sells

Rank Stock Value
1
V icon
Visa
V
+$139M
2
JNJ icon
Johnson & Johnson
JNJ
+$45.8M
3
ECL icon
Ecolab
ECL
+$41.6M
4
UNH icon
UnitedHealth
UNH
+$33.4M
5
PFE icon
Pfizer
PFE
+$32.3M

Sector Composition

Rank Sector Weight
1 Financials 24.06%
2 Consumer Discretionary 16.59%
3 Healthcare 13.94%
4 Consumer Staples 10.32%
5 Materials 7.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
101
Eli Lilly
LLY
$1.09T
– –
-91,848
Closed -$11.9M
NEO icon
102
NeoGenomics
NEO
$2.05B
– –
-149,378
Closed -$3.06M
PBYI icon
103
Puma Biotechnology
PBYI
$399M
– –
-39,179
Closed -$1.52M
RARE icon
104
Ultragenyx Pharmaceutical
RARE
$2.52B
– –
-38,168
Closed -$2.65M
HIND
105
Vyome Holdings
HIND
$14.5M
– –
0
– -$395K
SUPN icon
106
Supernus Pharmaceuticals
SUPN
$2.74B
– –
-17,325
Closed -$607K
TAK icon
107
Takeda Pharmaceutical
TAK
$56.5B
– –
-366,380
Closed -$7.46M
VKTX icon
108
Viking Therapeutics
VKTX
$3.89B
– –
-232,138
Closed -$2.31M
VTRS icon
109
Viatris
VTRS
$20.8B
– –
-257,473
Closed -$7.3M
ITCI
110
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-146,671
Closed -$1.79M
PRTK
111
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-470,150
Closed -$2.52M
FSTX
112
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-13,025
Closed -$547K
CLVS
113
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-63,530
Closed -$1.58M
CERN
114
DELISTED
Cerner Corp
CERN
– –
-50,329
Closed -$2.88M
XENT
115
DELISTED
Intersect ENT, Inc
XENT
– –
-123,514
Closed -$3.97M
ALXN
116
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-47,325
Closed -$6.4M
AIMT
117
DELISTED
Aimmune Therapeutics
AIMT
– –
-182,709
Closed -$4.08M
PFNX
118
DELISTED
Pfenex Inc.
PFNX
– –
-352,153
Closed -$2.18M
AGN
119
DELISTED
Allergan plc
AGN
– –
-75,890
Closed -$11.1M
FOMX
120
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-442,884
Closed -$1.66M
DERM
121
DELISTED
Dermira, Inc.
DERM
– –
-324,884
Closed -$4.4M
ONCE
122
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-37,392
Closed -$4.26M
CELG
123
DELISTED
Celgene Corp
CELG
– –
-97,986
Closed -$9.24M
1 2 3 4
5

Similar funds

ASC
Atalanta Sosnoff Capital New York $4.66B AUM 41.34% 1-Year Est. Return
MA
Mutual Advisors Omaha, Nebraska $4.67B AUM 17.48% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
VCM
Voleon Capital Management Berkeley, California $4.64B AUM 38.78% 1-Year Est. Return
LPPI
Local Pensions Partnership Investment London, United Kingdom $4.63B AUM 13.51% 1-Year Est. Return
CCWM
Cassaday & Co Wealth Management Mclean, Virginia $4.69B AUM 20.56% 1-Year Est. Return

C WorldWide Group's Q2 2019 Portfolio in Review

As of Q2 2019, C WorldWide Group held 123 positions worth $8.04B, up 2.1% from $7.88B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

C WorldWide Group withdrew a net $244M in Q2 2019, closing 40 positions and reducing 37 holdings. Its most notable exit was Amgen, an estimated $15.3M position sold in full.

By sector, the portfolio is most concentrated in Financials at 24% of assets, up from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.

Against the trend, C WorldWide Group opened a new position in MSCI worth $183M.

  • C WorldWide Group's largest Q2 2019 buy was MSCI: 764,587 shares worth $183M.
  • C WorldWide Group added most to Elevance Health in Q2 2019, an estimated $30.9M increase.
  • C WorldWide Group's biggest Q2 2019 reduction was Visa, cutting an estimated $139M.
  • C WorldWide Group fully exited Amgen in Q2 2019, selling an estimated $15.3M.
  • C WorldWide Group's ten largest holdings make up 73% of its $8.04B portfolio in Q2 2019.
  • C WorldWide Group opened 10 new positions and closed 40 in Q2 2019.
  • C WorldWide Group's portfolio value rose 2.1% quarter-over-quarter to $8.04B.

Based on C WorldWide Group's 13F filing for Q2 2019, filed 2 Aug 2019.